LNP023
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis
Conditions
Glomerulonephritis
Trial Timeline
Feb 20, 2019 → Apr 23, 2021
NCT ID
NCT03832114About LNP023
LNP023 is a phase 2 stage product being developed by Novartis for Glomerulonephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03832114. Target conditions include Glomerulonephritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06934967 | Phase 3 | Recruiting |
| NCT06931691 | Pre-clinical | Recruiting |
| NCT04557462 | Phase 3 | Recruiting |
| NCT03955445 | Phase 3 | Recruiting |
| NCT03896152 | Phase 2 | Completed |
| NCT03832114 | Phase 2 | Completed |
| NCT03373461 | Phase 2 | Completed |
Competing Products
8 competing products in Glomerulonephritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |